Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as antagonists of the NMDA receptor-channel complex

Journal of Medicinal Chemistry

Volumn 40, Issue 18, 1997, Pages 2922-2930

  Grauert, Matthias ^a   Bechtel, Wolf Dietrich ^a   Ensinger, Helmut A ^a   Merz, Herbert ^a   Carter, Adrian J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,5,6 HEXAHYDRO 3 (2 METHOXYPROPYL) 6,11,11 TRIMETHYL 2,6 METHANO 3 BENZAZOCIN 9 OL; BENZOMORPHAN; DIZOCILPINE; N ALLYLNORMETAZOCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN INJURY; CHEMICAL STRUCTURE; HUMAN; NEUROLOGIC DISEASE; PATHOGENESIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BENZOMORPHANS; BINDING, COMPETITIVE; CELL MEMBRANE; CEREBRAL CORTEX; CRYSTALLOGRAPHY, X-RAY; DIHYDROMORPHINE; DIZOCILPINE MALEATE; ION CHANNELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MORPHINE DERIVATIVES; N-METHYLASPARTATE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES;

EID: 0030803236     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970131j     Document Type: Article

References (60)

1. Hicks, T. P. The role of glutamate and its receptors in synaptic transmission. In CNS Neurotransmitters and Neuromodulators: Glutamate; Stone, T. W., Ed.; CRC Press, Inc.: New York, 1995; pp 201-215.
2. (a) Hayashi, T. A physiological study of epileptic seizures following cortical stimulation in animals and its application to human clinics. Jpn. J. Physiol. 1952, 3, 46-64.
3. (b) Lucas, D. R.; Newhouse, J. P. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Archives of Opthalmology 1957, 58, 193-201.
4. (c) Fifkova, E.; Van Harreveld, A. Glutamate effects in the developing chicken. Exp. Neurol. 1970, 28, 286-298.
5. (d) Van Harreveld, A.; Fifkova, E. Light- and electron-microscopic changes in central nervous tissue after electrophoretic injection of glutamate. Exp. Mol. Pathol. 1971, 15, 61-81.
6. (e) Rothman, S. M. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J. Neurosci. 1984, 4, 1884-1891.
7. Benveniste, H.; Drejer, J.; Schouseboe, A.; Diemer, N. H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 1984, 43, 1369-1374.
8. (a) Rothmann, S. M.; Olney, J. W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 1986, 19, 105-111.
9. (b) Olney, J. W. Excitotoxic amino acids and neuropsychatric disorders. Annu. Rep. Pharmacol. Toxicol. 1990, 30, 47-71.
10. (c) Meldrum, B.; Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 1990, 11, 379-387.
11. (d) Coyle, J. T.; Puttfricken, P. Oxidative stress, glutamate and neurodegenerative disorders. Science 1993, 262, 689-694.
12. (e) Lipton, S. A.; Rosenberg, P. A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med 1994, 330, 613-622.
13. (a) Watkins, J. C.; Evans, R. H. Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol. 1981, 21, 165-204.
14. (b) Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258, 597-603.
15. (a) Barnes, J. M.; Henley, J. M. Molecular characteristics of excitatory amino acid receptors. Prog. Neurobiol. 1992, 39, 113-133.
16. (b) Gasic, G. P.; Hollmann, M. Molecular neurobiology of glutamate receptors. Annu. Rev. Physiol. 1992, 54, 507-536.
17. (a) Simon, R. P.; Swan, J. H.; Griffiths, T.; Meldrum, B. S. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984, 226, 850-852.
18. (b) Faden, A. I.; Demediuk, P.; Panter, S. S.; Vink. R. The role of excitatory ammo acids and NMDA receptors in traumatic brain injury. Science 1989, 244, 798-800.
19. (c) Ozyurt, E.; Graham, D. I.; Woodruff, G. N.; McCulloch, J. Protective effect of the glutamate antagonist MK-801 in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 1988, 8, 128-143.
20. (d) Park, C. K.; Nehls, D. G.; Graham, D. I.; Teasale, G. M.; McCulloch, J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol. 1988, 24, 543-551.
21. (e) McCulloch, J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br. J. Clin. Pharmacol. 1992, 34, 106-114.
22. (f) Gill, R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc. Brain Metab. Rev. 1994, 6, 225-256.
23. Hille, B. Ionic channels of excitable membranes; Sinauer Associates Inc.: Sunderland, MA, 1992; pp 166-169.
24. (a) Reynolds, I. J.; Miller, R. J. Multiple sites for the regulation of the N-methyl-D-aspartate receptor. Mol. Pharmacol. 1988, 33, 581-584.
25. (b) Carter, A. J. Glycine antagonists; Regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future 1992, 17, 595-613.
26. Wong, E. H. F.; Kemp, J. A.; Priestley, T.; Knight, A. R.; Woodruff, G. N.; Iversen, L. L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 7104-7108.
27. Fragg, G. E. Phencyclidine and related drugs bind to the rat brain membranes. Neurosci. Lett. 1987, 6, 221-227.
28. (a) Anis, N. A.; Berry, S. C.; Burton, N. R.; Lodge, D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce exitation of central mammalian neurons by N-methyl-D-aspartate. Br. J. Pharmacol. 1983, 79, 565-575.
29. (d) Honey, C. R.; Miljkovic, Z.; MacDonald, J. F. Ketamine and phencylidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci. Lett. 1985, 61, 135-139.
30. Reddy, N. L.; Hu, L.-Y.; Cotter, R. E.; Fischer, J. B.; Wong, W. J.; McBurney, R. N.; Weber, E.; Holmes, D. L.; Wong, S. T.; Prasad, R.; Keana, J. F. W. Synthesis and structure-activity studies of N,N′-diarylguanidine derivatives. N-(1-naphthyl)-N′-(3-ethylphenyl)-N′-methylguanidine: A new, selective noncompetitive NMDA receptor antagonist. J. Med. Chem. 1994, 37, 260-267.
31. Foster, A. C. Channel blocking drugs for the NMDA receptor. In Excitatory Amino Acid Antagonists; Meldrum, B. S., Ed.; Blackwell: Oxford, 1991; pp 164-179.
32. (a) Huettner, J. E.; Bean, B. P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 1307-1311.
33. (b) Rogawski, M. A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 1993, 14, 325-331.
34. Carroll, F. I.; Abraham, P.; Parham, K.; Bai, X.; Zhang, X.; Brine, G. A.; Mascarella, S. W.; Martin, B. R.; May, E. L.; Sauss, C.; Di Paolo, L.; Wallace, P.; Walker, J. M.; Bowen, W. D. Enantiomeric N-substituted N-normetazocines: A comparative study of affinites at σ, PCP, and μ opioid receptors. J. Med. Chem. 1992, 35, 2812-2818.
35. (b) Rothman, R. B.; Reid, A. A.; Monn; J. A. Jacobson, A. E.; Rice, K. C. The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: Evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencylidine binding sites. Mol. Pharmacol. 1989, 36, 887-896. Reid, A. A.; Mattson, M. V.; De Costa, B. R.; Thurkauf, A.; Jacobson, A. E.; Monn, J. A.; Rice, K. C.; Rothman, R. B. Specificity of phencyclidine-like drugs and benzomorphan opiates for two high affinity phencyclidine binding sites in guinea pig brain. Neuropharmacology 1990, 29, 811-817.
36. (b) Rothman, R. B.; Reid, A. A.; Monn; J. A. Jacobson, A. E.; Rice, K. C. The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: Evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencylidine binding sites. Mol. Pharmacol. 1989, 36, 887-896. Reid, A. A.; Mattson, M. V.; De Costa, B. R.; Thurkauf, A.; Jacobson, A. E.; Monn, J. A.; Rice, K. C.; Rothman, R. B. Specificity of phencyclidine-like drugs and benzomorphan opiates for two high affinity phencyclidine binding sites in guinea pig brain. Neuropharmacology 1990, 29, 811-817.
37. Carter, A. J. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination. J. Pharmacol. Exp. Ther. 1994, 269, 573-580.
38. (a) Olney, J. W.; Labruyere, J.; Price, M. T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244, 1360-1362.
39. (b) Trickelbank, M. D.; Singh, L.; Oles, R. J.; Preston, C.; Iversen, S. D. The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 1989, 167, 127.
40. (c) Hargreaves, R. J.; Rigby, M.; Smith, D.; Hill, R. G.; Iversen, L. L. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem. Res. 1993, 18, 1263-1269.
41. (a) Martin, W. R.; Eades, C. E.; Thompson, J. A.; Huppler, R. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197, 517-532.
42. (b) Magnan, J.; Patterson, S. J.; Tavani, A.; Kosterlitz, H. W. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch. Pharmacol. 1982, 197-319.
43. (c) Quiron, R.; Chicheportiche, R.; Contreras, P. C.; Johnson, K. M.; Lodge, D.; Tam, S. W.; Woods, J. H.; Zukin, S. R. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurol. Sci. 1987, 10, 444-446.
44. Zukin, S. R. Differing stereospecificities distinguish opiate receptor subtypes. Life Sci. 1982, 31, 1307-1310.
45. Carter, A. J.; Bechtel, W. D.; Grauert, M.; Harrisson, P.; Merz, H.; Stransky, W. BIII 277 CL is a potent and specific ion-channel blocker of the NMDA receptor-channel complex. J. Pharmacol. Exp. Ther. 1995, 275, 1382-1389.
46. (a) Tullar, B. F.; Harris, L. S.; Perry, R. L.; Pierson, A. K.; Soria, A. E.; Wetterau, W. F.; Albertson, N. F. Benzomorphans. Optically active and trans isomers. J. Med. Chem. 1967, 10, 383-386.
47. (b) Brine, G. A.; Berrang, B.; Hayes, J. P.; Carroll, F. I. An improved resolution of (±)-cis-N-normetazocine. J. Heterocycl. Chem. 1990, 27, 2139-2143.
48. (a) Kochetkov, N. K. The total synthesis of some pyrrolyzidine alkaloids and their absolute configuration. Tetrahedron 1969, 25, 2313-2323.
49. (b) Owen, L. N.; Rahman, M. B. The synthesis and reduction of optically active 2-mercaptopropionic acid and some derivatives. J. Chem. Soc. C 1971, 2432-2440.
50. Rahtz, D.; Paschelke, G.; Schröder, E. Neue N-2-Hydroxy-alkyl-6,7-benzomorphanderivate: Synthese und orientierende pharmakologische Prüfung. Eur. J. Med. Chem. Chim. Ther. 1977, 12, 271-278.
51. (a) Merz, H.; Stockhaus, K. N-[(Tetrahydrofuryl)alkyl] and N-(alkoxyalkyl) derivatives of (-)-normetazocine, compounds with differentiated opioid action profiles. J. Med. Chem. 1979, 22, 1475-1483.
52. (b) May, E. L.; Aceto, M. D.; Bowman, E. R.; Bentley, C.; Martin, B. R.; Harris, L. S.; Medzihradsky, F.; Mattson, M. V.; Jacobson, A. E. Antipodal α-N-(methyl through decyl)-N-normetazocines (5,9α-dimethyl-2′-hydroxy-6,7-benzomorphans): In vitro and in vivo properties. J. Med. Chem. 1994, 37, 3408-3418.
53. Schmidhammer, H.; Aeppli, L.; Atwell, L.; Fritsch, F.; Jacobson, A. E.; Nebuchla, M.; Sperk, G. Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)14-methoxy-N-methylmorphinan-6-ones. J. Med. Chem. 1984, 27, 1575-1579.
54. Jaffe, J. H.; Martin, W. R. Opioid analgesics and antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Vol. 8th; Goodman, A. G., Rall, T. W., Nies, A. S., Taylor, P., Eds.; McGraw-Hill: New York, 1995; pp 485-521.
55. Grauert, M.; Rho, J. M.; Rogawski, M. A. BIII 277 CL and BIII 281 CL, two enantiomeric NMDA open-channel blockers: electrophysiological characterization. Soc. Neurosci. Abstr. 1995, 21, 436.2.
56. Pschorn, U.; Carter, A. J. The influence of repeated doses, route and time of administration on the neuroprotective effects of BIII 277 CL in a rat model of focal cerebral ischemia. J. Stroke Cerebrovasc. Dis. 1996, 6, 93-99.
57. Sheldrick, G. M. SHELXTL-PLUS, an integrated system for solving, refining and displaying crystal structures from diffraction data; University of Göttingen, 1990.
58. Rogers, D. On the application of Hamilton's ratio test to the assignment of absolute configuration and an alternative test. Acta Crystallogr. 1981, A37, 734-741.
59. 3H]Mr 2023 labels a high affinity opioid kappa-receptor not accessible to naloxazone. Eur. J. Pharmacol. 1983, 89, 143-147.
60. Rominger, K. L.; Albert, H. J. Radioimmunological determination of fenoterol part I. Theoretical fundamentals. Drug Res. 1985, 35, 415-420.